NU7441 (KU-57788)

Name: NU7441 (KU-57788)
Brand: Selleck Chemicals
SKU: S2638
Rating: 5 (174 reviews)

For research use only.

Catalog No.S2638

174 publications

CAS No. 503468-95-9

NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.

Selleck's NU7441 (KU-57788) has been cited by 174 publications

Immunity, 2021, S1074-7613(21)00069-8

PubMed: 33667382 ( click the link to review the publication )

Cell Res, 2021, 10.1038/s41422-021-00528-3

PubMed: 34239070 ( click the link to review the publication )

Nature, 2020, 10.1038/s41586-020-2960-y

PubMed: 33239783 ( click the link to review the publication )

Nature, 2019, 74(7779):571-574

PubMed: 31645724 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):396-410

PubMed: 30205044 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(5):463-474

PubMed: 28319085 ( click the link to review the publication )

Sci Transl Med, 2021, 13(600)eabc7275

PubMed: 34193614 ( click the link to review the publication )

Sci Adv, 2021, 7(25)eabg6680

PubMed: 34144993 ( click the link to review the publication )

J Clin Invest, 2021, 131(11)146256

PubMed: 34060485 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkab262

PubMed: 33877327 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkab743

PubMed: 34428289 ( click the link to review the publication )

Nucleic Acids Res, 2021, 49(9):5095-5105

PubMed: 33963863 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):224

PubMed: 34225780 ( click the link to review the publication )

Cancers (Basel), 2021, 13(4)830

PubMed: 33669398 ( click the link to review the publication )

Int J Biol Sci, 2021, 17(4):1026-1040

PubMed: 33867826 ( click the link to review the publication )

Int J Biol Sci, 2021, 17(4): 1026-1040

PubMed: N/A ( click the link to review the publication )

Int J Mol Sci, 2021, 22(19)10512

PubMed: 34638853 ( click the link to review the publication )

Mol Cancer Res, 2021, molcanres.0301.2021

PubMed: 34330845 ( click the link to review the publication )

Acta Pharmacol Sin, 2021, 10.1038/s41401-020-00577-1

PubMed: 33414509 ( click the link to review the publication )

Cell Signal, 2021, S0898-6568(21)00195-9

PubMed: 34363951 ( click the link to review the publication )

Biochem Biophys Res Commun, 2021, 553:51-57

PubMed: 33756345 ( click the link to review the publication )

Mol Biol Rep, 2021, 10.1007/s11033-020-06124-9

PubMed: 33389482 ( click the link to review the publication )
FEBS Open Bio, 2021, 10.1002/2211-5463.13198

PubMed: 33999508 ( click the link to review the publication )

Commun Biol, 2021, 4(1):484

PubMed: 33875784 ( click the link to review the publication )

Sci Transl Med, 2021, 13(580)eabc4465

PubMed: 33568520 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkab051

PubMed: 33591315 ( click the link to review the publication )

Blood, 2020, 5 pii: blood

PubMed: 32369572 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(20):2000157

PubMed: 33101843 ( click the link to review the publication )

Mol Cell, 2020, S1097-2765(20)30723-1

PubMed: 33152268 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6182

PubMed: 33273464 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5775

PubMed: 33188175 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa022

PubMed: 31965183 ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa782

PubMed: 33010172 ( click the link to review the publication )

Sci Immunol, 2020, 5(43)

PubMed: 31980485 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-20-2269

PubMed: 32967938 ( click the link to review the publication )

J Cell Biol, 2020, 219(11)e202001063

PubMed: 33007086 ( click the link to review the publication )

Cell Rep, 2020, 32(8):108068

PubMed: 32846126 ( click the link to review the publication )

Cell Rep, 2020, 32(11):108140

PubMed: 32937135 ( click the link to review the publication )

Cell Rep, 2020, 33(2):108240

PubMed: 33053351 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 4;5(1):20

PubMed: 32296021 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0507

PubMed: 32229503 ( click the link to review the publication )

Front Oncol, 2020, 10:575711

PubMed: 33178606 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(17)E6383

PubMed: 32887472 ( click the link to review the publication )

Int J Oncol, 2020, 57(4):939-955

PubMed: 32945394 ( click the link to review the publication )

Int J Radiat Biol, 2020, 1-7

PubMed: 33074046 ( click the link to review the publication )
J Cell Physiol, 2020, 10.1002/jcp.29927

PubMed: 32686190 ( click the link to review the publication )

Nucleic Acids Res, 2020, 48(2):736-747

PubMed: 31740976 ( click the link to review the publication )

University of Lübeck, 2020, N/A

PubMed: None ( click the link to review the publication )

Cancers (Basel), 2020, 12(9):E2356

PubMed: 32825402 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):1490

PubMed: 32517381 ( click the link to review the publication )

Oncotarget, 2020, 11(7):699-726

PubMed: 32133046 ( click the link to review the publication )

NAR Cancer, 2020, 2(2):zcaa006

PubMed: 32743550 ( click the link to review the publication )

Elife, 2020, 9:e57894

PubMed: 32628111 ( click the link to review the publication )

J Biol Chem, 2020, 295(1):125-137

PubMed: 31753920 ( click the link to review the publication )

Int J Mol Med, 2020, 45(6):1673-1684

PubMed: 32186748 ( click the link to review the publication )

Cell Rep, 2020, 32(6):108018

PubMed: 32783940 ( click the link to review the publication )

Toxicol Lett, 2020, 318:104-113

PubMed: 31672611 ( click the link to review the publication )

Biomed Pharmacother, 2020, 129:110427

PubMed: 32574974 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5304

PubMed: 31757956 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1577

PubMed: 30952868 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3925

PubMed: 31477700 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2866

PubMed: 31253785 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(18):5608-5622

PubMed: 31266829 ( click the link to review the publication )

Genes Dev, 2019, 33(17-18):1175-1190

PubMed: 31395742 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

J Cell Biol, 2019, 218(7):2113-2123

PubMed: 31123184 ( click the link to review the publication )

Cell Rep, 2019, 29(11):3708-3725.e5

PubMed: 31825846 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32558

PubMed: 31283004 ( click the link to review the publication )

Oncogene, 2019, 38(14):2451-2463

PubMed: 30532030 ( click the link to review the publication )
Cancers (Basel), 2019, 11(9)

PubMed: 31480356 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):600-610

PubMed: 31481733 ( click the link to review the publication )

FASEB J, 2019, 33(1):1138-1150

PubMed: 30106602 ( click the link to review the publication )

FASEB J, 2019, 33(11):11668-11681

PubMed: 31348687 ( click the link to review the publication )

FASEB J, 2019, 33(6):6778-6788

PubMed: 30807703 ( click the link to review the publication )

PLoS Genet, 2019, 15(2):e1007925

PubMed: 30716077 ( click the link to review the publication )

J Environ Manage, 2019, 244:77-82

PubMed: 31108313 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2457-2468

PubMed: 31551253 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz178

PubMed: 31388677 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(24)E6316

PubMed: 31847370 ( click the link to review the publication )

J Biol Chem, 2019, 294(8):2827-2838

PubMed: 30598506 ( click the link to review the publication )

Mol Cell Biol, 2019, 39(24)e00181-19

PubMed: 31591143 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 371(2):320-326

PubMed: 31455631 ( click the link to review the publication )

Retrovirology, 2019, 16(1):13

PubMed: 31036006 ( click the link to review the publication )

Front Physiol, 2019, 10:616

PubMed: 31178753 ( click the link to review the publication )

BMC Pulm Med, 2019, 19(1-:165

PubMed: 31464599 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-04605-0

PubMed: 31020489 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-05105-x

PubMed: 31583565 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3609-3616

PubMed: 31485633 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(7):1315-1326

PubMed: 31141305 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(21):10977-10993

PubMed: 31612207 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(18):9467-9479

PubMed: 31396623 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(16):8838-8859

PubMed: 31329944 ( click the link to review the publication )

Cell Res, 2018, 28(7):756-770

PubMed: 29844578 ( click the link to review the publication )
Nat Commun, 2018, 9(1):5351

PubMed: 30559436 ( click the link to review the publication )

Cell Rep, 2018, 24(4):987-1000

PubMed: 30044993 ( click the link to review the publication )

Int J Cancer, 2018,

PubMed: 29363109 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):931

PubMed: 30209297 ( click the link to review the publication )

FASEB J, 2018, 32(4):1818-1829

PubMed: 29162700 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(23):4024-4035

PubMed: 30107443 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(8):1241-1254

PubMed: 29739874 ( click the link to review the publication )

DNA Repair (Amst), 2018, 68:68-74

PubMed: 30017059 ( click the link to review the publication )

Mol Biol Cell, 2018, 29(15):1786-1797

PubMed: 29897835 ( click the link to review the publication )

Int J Mol Sci, 2018,

PubMed: 30115874 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9685

PubMed: 29946146 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5050-5060

PubMed: 29660033 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(17):8926-8939

PubMed: 30113698 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14421

PubMed: 30258062 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

JCI Insight, 2018, 3(3)98096

PubMed: 29415883 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(1):244-254

PubMed: 28069995 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(9):790-803

PubMed: 28775208 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4567-4578

PubMed: 28698210 ( click the link to review the publication )

Cancer Res, 2017, 77(18):4745-4754

PubMed: 28754673 ( click the link to review the publication )

J Cell Biol, 2017, 216(3):623-639

PubMed: 28228534 ( click the link to review the publication )
EMBO Rep, 2017, 18(8):1412-1428

PubMed: 28615293 ( click the link to review the publication )

Cell Death Discov, 2017, 3:17072

PubMed: 29090098 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12424-12435

PubMed: 28592488 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 92:164-172

PubMed: 28827033 ( click the link to review the publication )

Radiat Res, 2017, 188(6):597-604

PubMed: 28952912 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181608

PubMed: 28750002 ( click the link to review the publication )

DNA Repair (Amst), 2017, 54:30-39

PubMed: 28448822 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Oncotarget, 2017, 8(2):2916-2935

PubMed: 27935866 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(11):1196-1207

PubMed: 27723717 ( click the link to review the publication )

blood, 2016, 10.1182/blood-2016-02-700328

PubMed: ( click the link to review the publication )

Blood, 2016, 128(4):574-83

PubMed: 27235137 ( click the link to review the publication )

Nat Commun, 2016, 7:12880

PubMed: 27634057 ( click the link to review the publication )

Oncogene, 2016, 35(5):577-586

PubMed: 25893305 ( click the link to review the publication )

Cancer Lett, 2016, 383(1):41-52

PubMed: 27693461 ( click the link to review the publication )

Cell Death Dis, 2016, 7(7):e2316

PubMed: 27468692 ( click the link to review the publication )

Sci Rep, 2016, 6:22972

PubMed: 27026501 ( click the link to review the publication )

Cell Cycle, 2016, 15(1):84-94

PubMed: 26771713 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0167454

PubMed: 27907109 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163049

PubMed: 27643854 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(11):5204-17

PubMed: 27001513 ( click the link to review the publication )

Oncotarget, 2016, 7(38):60807-60822

PubMed: 27602502 ( click the link to review the publication )
Nucleic Acids Res, 2016, 44(8):3695-712

PubMed: 26843428 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65504-65513

PubMed: 27602767 ( click the link to review the publication )

Mutat Res Genet Toxicol Environ Mutagen, 2016, 795:1-6

PubMed: 26774662 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(9):1158-68

PubMed: 26237645 ( click the link to review the publication )

Leukemia, 2015, 29(5):1133-42

PubMed: 25371178 ( click the link to review the publication )

Genome Med, 2015, 10.1186/s13073-015-0215-6

PubMed: 26307031 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(8):1896-906

PubMed: 26026052 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

J Biol Chem, 2015, 290(46):27545-56

PubMed: 26420486 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(11):1585-92

PubMed: 26382920 ( click the link to review the publication )

Cell Cycle, 2015, 14(23):3713-24

PubMed: 26505547 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26065416 ( click the link to review the publication )

Anticancer Res, 2015, 35(7):3829-38

PubMed: 26124328 ( click the link to review the publication )

Oncotarget, 2015, 6(16):14005-25

PubMed: 26087309 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(12):7776-92

PubMed: 24906880 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(9):5616-32

PubMed: 24598253 ( click the link to review the publication )

Genes Dev, 2014, 28(8):875-87

PubMed: 24700029 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4282-94

PubMed: 24894717 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.268

PubMed: 25132265 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Toxicol Sci, 2014, 10.1093/toxsci/kfu207

PubMed: 25288669 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2014,

PubMed: ( click the link to review the publication )
Uppsala University, 2014, Department of Radiology

PubMed: ( click the link to review the publication )

Mutat Res, 2014, 769:1-10

PubMed: 25771720 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(22):10157-69

PubMed: 24021630 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(7):4080-92

PubMed: 23449221 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(15):7378-86

PubMed: 23775790 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2013, 88(2):385-94

PubMed: 24411611 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA-PK Inhibitors

Biological Activity

Description

Targets

DNA-PK ^[1] (Cell-free assay)	mTOR ^[1] (cell-free assay)	PI3K ^[1] (cell-free assay)
14 nM	1.7 μM	5 μM

In vitro

NU7441 increases the persistence of γH2AX foci after ionizing radiation–induced or etoposide-induced DNA damage. NU7441 (0.5 μM or 1 μM) appreciably increases G2-M accumulation induced by ionizing radiation, etoposide, and doxorubicin in both SW620 and LoVo cells. ^[2] NU7441 causes persistence of doxorubicin- and ionising radiation-induced DNA double-strand break and also slightly decreases homologous recombination activity DNA-PK-proficient M059-Fus-1 and DNA-PK-deficient M059 J human tumour cells. ^[3] NU7441 inhibits UV-induced RPA p34 hyperphosphorylation in a dose-dependent manner both in cells lacking and cells expressing polymerase η. ^[4] NU7441 increases levels of fludarabine-induced γH2AX foci and correspondingly decreased fludarabine-induced cell death in chronic lymphocytic leukemia cells. ^[5] NU7441 also inhibits mitoxantrone-induced DNA-PKcs autophosphorylation and repair in chronic lymphocytic leukemia cells. ^[6] It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage^[7].

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
NCI-H1770	M3Ta[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX7JR\|UxRTBwMEKxOFMh\|ryP	MmPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
A172	NY\NO25WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4HscGlEPTB;MD6xOVMyPiEQvF2=	NI\CU3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H526	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1SwZWlEPTB;MD6yPFQxPyEQvF2=	NXnYcpZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HDLM-2	MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NISzOVhKSzVyPUCuN\|I{PDVizszN	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HuO-3N1	NV3RXJc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mn3ITWM2OD1yLkS2OlM3KM7:TR?=	NGrZVYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-SNU-1	NWLkZ\|RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mn30TWM2OD1yLk[wPVk1KM7:TR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-N-AS	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVvWR5NGUUN3ME2wMlYzOjF4IN88US=>	M1jh[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
LoVo	MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M33Sc2lEPTB;MD64Olc1QSEQvF2=	NG\sR4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
LAMA-84	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV3JR\|UxRTBwOUi4N\|Mh\|ryP	Moj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CTB-1	MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2H1UWlEPTB;MT6xNVU1PiEQvF2=	NEPON409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KP-N-YS	MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3rTRWlEPTB;MT6xOFI{OSEQvF2=	M{O2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HH	NXzm[XF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmPyTWM2OD1zLkG4NFk{KM7:TR?=	M160dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
CHL-1	M2HXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYHJR\|UxRTFwMkGzOlgh\|ryP	MoO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NB7	NFH1fI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIDDeGVKSzVyPUGuNlQ4PDVizszN	M4XITlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HL-60	NHjXN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVvJR\|UxRTFwM{ixPUDPxE1?	M2XGTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
639-V	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlvvTWM2OD1zLkS0NVI5KM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H1793	MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3TNXWlEPTB;MT60OVg1KM7:TR?=	NHO2bZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NEC8	MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1zRW2lEPTB;MT61OVM2KM7:TR?=	NUHibYtURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
PA-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFPodVVKSzVyPUGuOVgzQTRizszN	NXG1WHp2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
D-423MG	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2jSdmlEPTB;MT62PVM3OSEQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H292	Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXricnB[UUN3ME2xMlc1ODF\|IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-MEL-1	NHTKVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVPkdVFYUUN3ME2xMlc6PDd7IN88US=>	M17jZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
LB2241-RCC	M{nt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYXJR\|UxRTJwMUSxOFYh\|ryP	NWrjXHFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SK-MEL-3	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlfjTWM2OD1{LkG2OFkh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MHH-PREB-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHjW[GVKSzVyPUKuNVY3ODlizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
BFTC-905	MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NU\M[Yd[UUN3ME2yMlE3Pjh5IN88US=>	Mn:4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
Ramos-2G6-4C10	NGjq[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoLBTWM2OD1{LkG5PVA6KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
G-361	NETNSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUXJR\|UxRTJwMkG2PEDPxE1?	NGHYcHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MOLT-4	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXjJR\|UxRTJwMkG4PFgh\|ryP	M1;2SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
DEL	MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVLJR\|UxRTJwM{W1OlQh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MV-4-11	M4PXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3LlZWlEPTB;Mj6zO\|M6KM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-NEP-1	NFzlZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGi0[HNKSzVyPUKuN\|g4QDNizszN	NYHyW45mRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
RS4-11	NEHNUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnLpTWM2OD1{LkW2NFI{KM7:TR?=	M{\2TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HuH-7	M{LEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MY\JR\|UxRTJwNU[3NFIh\|ryP	MmHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
A101D	M{fzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1rYemlEPTB;Mj62NVM{QCEQvF2=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
KG-1	M3PKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NX;vcJY1UUN3ME2yMlY4QTJ2IN88US=>	NETPWZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KALS-1	NU[2NndbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXzk[YFGUUN3ME2yMlY6PjN\|IN88US=>	MlnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
VMRC-RCZ	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Ml7ETWM2OD1{Lke3N\|I5KM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-UT-1	NVjmS2JlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mnj6TWM2OD1\|LkG1N\|Eh\|ryP	NHn1cpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SW962	Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoH1TWM2OD1\|LkKwN\|UzKM7:TR?=	NXTmPFhVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
DBTRG-05MG	MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3zJNGlEPTB;Mz6yPFA5PSEQvF2=	MoHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
PANC-08-13	MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUDl[ot6UUN3ME2zMlQyOjd6IN88US=>	Ml;pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	NWrZVZU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MU\JR\|UxRTNwNEGzOFEh\|ryP	NEfiPZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-MEL-30	M1naU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVTJR\|UxRTNwNEK1PVgh\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
697	MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlnTTWM2OD1\|LkS0PVk{KM7:TR?=	NITMb5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NY	NHu0WYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4rGVWlEPTB;Mz60OVAzOiEQvF2=	M3fZTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
ES7	Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml3ZTWM2OD1\|LkS2O\|I6KM7:TR?=	M2fFTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
JVM-3	M1XIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1PqWmlEPTB;Mz60PFA4PyEQvF2=	NIS0eHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
U031	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXvJR\|UxRTNwNUmzOlgh\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
BHT-101	M{LtdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXLJR\|UxRTNwNUm5PFUh\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
8305C	MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1GwSWlEPTB;Mz62NVc{PiEQvF2=	M3nTUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
MG-63	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmfUTWM2OD1\|Lk[yOlc3KM7:TR?=	M1HyVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NOS-1	NFnRUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NETyd2tKSzVyPUOuOlU{OTJizszN	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
YH-13	Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2PodGlEPTB;Mz64O\|E5QSEQvF2=	NXHlSZBoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
LXF-289	NHTHb41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{LsfWlEPTB;Mz65NVA1OSEQvF2=	NF\SVWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
GOTO	NG[w[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFrNS5NKSzVyPUOuPVE1QSEQvF2=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
EKVX	MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXjJR\|UxRTRwMkK1NlQh\|ryP	NYTwXGU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CAL-51	MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mo\mTWM2OD12LkK0PFU1KM7:TR?=	NIXTVGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
AN3-CA	NVHtWpFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml3rTWM2OD12LkK1PFE{KM7:TR?=	M2Oy[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
IA-LM	Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVLJR\|UxRTRwMke5N\|Uh\|ryP	MkPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
KU-19-19	M{n6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2jvcmlEPTB;ND6zNlkzOSEQvF2=	MkfUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
A704	NUfIOlRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWD1V3NLUUN3ME20MlQxQDh6IN88US=>	NGTyT409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
RH-18	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWDJR\|UxRTRwNES5OVMh\|ryP	M1LvOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
IST-MEL1	NHjHdlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoD0TWM2OD12LkW4NlY{KM7:TR?=	M13jZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
LU-134-A	MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHHXPY9KSzVyPUSuOVk3QDVizszN	NWP5fXhMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SF126	MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHvMPINKSzVyPUSuOlA4OTVizszN	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
EFO-27	NWW3enFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mn3NTWM2OD12Lk[2OVI2KM7:TR?=	MmT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SN12C	NIDTW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYjJR\|UxRTRwN{G4PVgh\|ryP	NYjvWWlxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
L-363	NVzoUodyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkfVTWM2OD12Lke3NVE3KM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MEL-HO	NYH1W4V2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXjJR\|UxRTRwN{e5PFkh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
TYK-nu	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVXJR\|UxRTRwOECxNlgh\|ryP	NH6xboI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MDA-MB-415	NEHlOXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXPJR\|UxRTVwMECzNVQh\|ryP	M3vz[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HCC70	M{L1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4njfmlEPTB;NT6wN\|k{QSEQvF2=	NVnnT4ZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
IGROV-1	MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NG\ZNXdKSzVyPUWuNlUzQTJizszN	MlHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H1355	MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NISzNYRKSzVyPUWuNlk3KM7:TR?=	M4XRXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
23132-87	NV\reFZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXzJR\|UxRTVwM{KwNlQh\|ryP	M3P5XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NB69	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoTNTWM2OD13LkOyOFIh\|ryP	M4CwfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HSC-2	NGXwPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVvVe\|dSUUN3ME21MlQyPzd\|IN88US=>	NF22XpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
KYSE-410	MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnjNTWM2OD13LkS3OlM3KM7:TR?=	NF;CWnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
GCIY	MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3yyPWlEPTB;NT61NVM4QCEQvF2=	MnrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
A427	NUnHcI9oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEC0S5BKSzVyPUWuOVM3PjFizszN	NWi1c\|AxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
ChaGo-K-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVXRWm9YUUN3ME21MlU3PTl7IN88US=>	NYnMOlc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
PFSK-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVzJR\|UxRTVwNkKxPVQh\|ryP	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MLMA	M2nse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4HUOmlEPTB;NT64N\|YxPiEQvF2=	M4HjR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
RVH-421	NIi5Z\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M16wNmlEPTB;Nj6wO\|M{QCEQvF2=	NGTp[mg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
LB1047-RCC	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3nZTWlEPTB;Nj6xO\|UzOiEQvF2=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MHH-NB-11	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmKwTWM2OD14LkOyO\|IyKM7:TR?=	MofSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVTOSWlMUUN3ME22MlY{OjlzIN88US=>	M2TOZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
UM-UC-3	M1H0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MonYTWM2OD14Lk[0N\|M1KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
IST-SL1	M{HONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYDvdHJVUUN3ME22MlY6OzZ7IN88US=>	MnvYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NB14	M3W1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3HTfGlEPTB;Nj63PVc3OSEQvF2=	M{T2[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NBsusSR	NX;GepJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUTNc3pJUUN3ME22MlgzPTB{IN88US=>	NXrPXpN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
D-263MG	M3;zTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVLJR\|UxRTZwOUGwOlgh\|ryP	NVjxcYF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H2347	MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4PHeGlEPTB;Nj65N\|IyOyEQvF2=	NFXabWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
ES8	Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUjJR\|UxRTZwOUe1PFgh\|ryP	NEi0NFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
786-0	NFjoUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXLkXYk1UUN3ME23MlA6Pzh4IN88US=>	NGPoepI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
EPLC-272H	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVTJR\|UxRTdwMU[yOFYh\|ryP	Mon4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CAPAN-1	NXfpcmVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGq3eHBKSzVyPUeuNlQ{PTlizszN	NX\FRmk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H82	M3XlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVG0RoZTUUN3ME23MlI3PjV7IN88US=>	NWDQdmZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
G-402	MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHLKNnZKSzVyPUeuN\|AxPTFizszN	NImxeGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SW982	M1z3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWfJR\|UxRTdwM{CyNFMh\|ryP	NFLWXJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
OVCAR-4	NHj3N45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1XGVGlEPTB;Nz6zNVMzQCEQvF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
KARPAS-299	Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWPJR\|UxRTdwM{K2NlIh\|ryP	NVjnOoEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MIA-PaCa-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mo\BTWM2OD15LkO2PFI{KM7:TR?=	NXrlb2FTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
AU565	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWD2b3hHUUN3ME23MlU6QDN\|IN88US=>	NFTNTW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
GAMG	M1izXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnzRTWM2OD15Lk[0NVMyKM7:TR?=	NUfL[VEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HuO9	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnHhTWM2OD15LkexO\|Q{KM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
ACN	MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmriTWM2OD15Lke0N\|Mh\|ryP	MkjiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
RO82-W-1	M{DpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NELr[lZKSzVyPUeuO\|Q2OzNizszN	NWPUR4dDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NKM-1	M{Tuemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXvUOGZMUUN3ME23Mlc1QTV3IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CAL-12T	MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXXJR\|UxRTdwOUSzOVIh\|ryP	NXOw[ZRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
FADU	M2[xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWfJR\|UxRThwMEO2OVQh\|ryP	NWPWcGtoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H28	NIi0XHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnfKTWM2OD16LkG2PVYzKM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
LCLC-97TM1	NHvoelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIT3OlBKSzVyPUiuNlEyOjJizszN	MoXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CHP-134	M1;GTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVrJR\|UxRThwMkSxPFUh\|ryP	NGLUNIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HT-1080	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MU\JR\|UxRThwMkWwPVMh\|ryP	M1zXeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
PC-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIntSXVKSzVyPUiuNlc{QTJizszN	NV64OIdORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SNU-449	NYXCPYh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYjoN2dxUUN3ME24MlI4QTNizszN	MmfSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
VA-ES-BJ	M3SwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MY\JR\|UxRThwM{S2PFYh\|ryP	NXe0RZlSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HT	NIWyRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NX;DUXNnUUN3ME24MlM3PDlizszN	NHezSnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HOS	NUHCTGVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NELMNXhKSzVyPUiuN\|c2QDlizszN	MlfwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
KNS-62	NFq5S3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVrJR\|UxRThwM{e3OlIh\|ryP	MkTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
OAW-42	M4[xVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NH7Fe2NKSzVyPUiuPVU6PjRizszN	NFvCVHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
A549	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnK1TWM2OD17LkC5OlEzKM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CAKI-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYXJR\|UxRTlwMU[2NUDPxE1?	M4\3UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HCC1937	NWL2[oN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mof5TWM2OD17Lk[5PFY2KM7:TR?=	NFnqR\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
GI-ME-N	MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVfJR\|UxRTlwN{CxN\|ch\|ryP	MmXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
DU-4475	MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnflTWM2OD17Lkm2PVM6KM7:TR?=	NIXtU\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
EM-2	MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVPEdpVuUUN3ME2xNE4zPDJ4IN88US=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H1755	NVfmcFZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV3RcYhGUUN3ME2xNE4zPDJ6IN88US=>	NFr5Vmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H1437	M2jTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFvLPJlKSzVyPUGwMlU4OjVizszN	NVP0XGoyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
VM-CUB-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHKwWGpKSzVyPUGwMlYyPjRizszN	NEnzc5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
A2058	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2\3VWlEPTB;MUCuOlQxPCEQvF2=	MnrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
BPH-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NX\5T\|FoUUN3ME2xNE44OTR3IN88US=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NB5	NYnJSZRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUHJR\|UxRTFyLke1OVkh\|ryP	NHfCUnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
G-401	M4jKU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NX3y[op6UUN3ME2xNE44PjJ4IN88US=>	NUG0elF5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CAL-72	NIPUepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFfnN5JKSzVyPUGwMlgxQTRizszN	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-MEL-28	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXfJR\|UxRTFyLkiyNFIh\|ryP	NHHiRYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
C32	M3q1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M37HfWlEPTB;MUCuPFM1PyEQvF2=	MlfWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H1155	M{fDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnjxTWM2OD1zMD64N\|c3KM7:TR?=	MmPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
BB49-HNC	NGLVeodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXTTbIxOUUN3ME2xNE45PTh4IN88US=>	MmO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
GMS-10	NYPTSWhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoS3TWM2OD1zMD64PVcyKM7:TR?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
K5	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2XPb2lEPTB;MUCuPVA4OSEQvF2=	NWPib4tURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
OS-RC-2	Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2HUXmlEPTB;MUGuNFU2QSEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HTC-C3	M4jnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NX7VVI9OUUN3ME2xNU4xPzF2IN88US=>	NU[zeotlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
LB996-RCC	Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVnJR\|UxRTFzLkC3NlMh\|ryP	NVXVNXlwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H1563	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXi1TlJVUUN3ME2xNU4yODFzIN88US=>	NF2z[\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
CAL-54	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2PUN2lEPTB;MUGuOFgyOSEQvF2=	M{DxTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
WM-115	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWLJR\|UxRTFzLk[4NlQh\|ryP	M17QfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
COLO-684	NX\qfWJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYWwcYhrUUN3ME2xNU44OjZ5IN88US=>	MnnYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HOP-62	MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4HS[2lEPTB;MUGuO\|UxQCEQvF2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H650	NHi1e3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NI\OeFJKSzVyPUGxMlg6PjFizszN	NYHXR2ZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
TE-11	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVfJR\|UxRTFzLkmzNVUh\|ryP	NV\vNIZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
COLO-679	NUDOWppCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGHDW21KSzVyPUGxMlk1PiEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
FTC-133	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3vnR2lEPTB;MUKuNFA4PiEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
D-283MED	MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1ewOmlEPTB;MUKuNFU3QSEQvF2=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SK-PN-DW	NHrGZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXTJR\|UxRTF{LkG5NFIh\|ryP	NHzmTIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
BALL-1	MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIqxUZNKSzVyPUGyMlI3PjJizszN	NU\1OohbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
GT3TKB	NECxd\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXHJR\|UxRTF{LkOwO\|Qh\|ryP	M4Hsd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HOP-92	Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{fSXGlEPTB;MUKuOVI{OyEQvF2=	MmHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
M14	NXT5Tlk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{\LR2lEPTB;MUOuNFM{PSEQvF2=	MnzOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SKG-IIIa	MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVj0bmJrUUN3ME2xN{4xPTV2IN88US=>	MlLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
Becker	M{PNPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVXkToxJUUN3ME2xN{4xPThizszN	M{HSfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
ES5	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIfBWFBKSzVyPUGzMlE{PTZizszN	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H2030	NVG3O\|BNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVHJR\|UxRTF\|LkKwOlIh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SNU-423	NXHYTY9xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUnJR\|UxRTF\|LkO4NUDPxE1?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CP50-MEL-B	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NHrWO5RKSzVyPUGzMlYzOzJizszN	NITUNmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H1092	NHfoUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVHJR\|UxRTF\|Lke0O\|Uh\|ryP	MnrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
8-MG-BA	M2LyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3v6eGlEPTB;MUOuO\|UyOyEQvF2=	NV\IVYI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CAL-27	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWjFboM{UUN3ME2xOE4xPzJ5IN88US=>	NYTZSYEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
AGS	NIrvdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmPXTWM2OD1zND6xN\|E6KM7:TR?=	NUHrOnNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MZ2-MEL	NULpSm5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4DPemlEPTB;MUSuNVQ5QCEQvF2=	NYW1VI5RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
BFTC-909	MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{TiZmlEPTB;MUSuOVA2PSEQvF2=	NHraZ2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
D-566MG	M2nLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVTYRWMxUUN3ME2xOE44PzB4IN88US=>	NFTOR5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MZ7-mel	MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlHETWM2OD1zNT6xNFY4KM7:TR?=	NITab2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
TE-5	NI\0[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYnEclVRUUN3ME2xOU4zOzN\|IN88US=>	NU\5XXRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
647-V	NF;LdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1;YRWlEPTB;MUWuNlcxPSEQvF2=	NYL0W21QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
DMS-114	NFHkS\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4\UZ2lEPTB;MUWuN\|I6OSEQvF2=	Mm\RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
ME-180	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4LWV2lEPTB;MUWuOFc5OyEQvF2=	MnvvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
MS-1	M3LjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYTxeIx2UUN3ME2xOU42PjJ\|IN88US=>	MoLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NUGC-3	M4S4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MY\JR\|UxRTF3Lk[yOFUh\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
GB-1	NEfrcYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml\xTWM2OD1zNT62OFM4KM7:TR?=	MnHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
LOXIMVI	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlXyTWM2OD1zNT64PVE6KM7:TR?=	M3fBWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H1304	M3qyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MljsTWM2OD1zNT64PVI5KM7:TR?=	MlfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
KURAMOCHI	MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mk\lTWM2OD1zNT65O\|Eh\|ryP	NHu1[lQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SW1783	M3LZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4LzcmlEPTB;MU[uNFk6OyEQvF2=	MmPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
EGI-1	NH7COJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYTTTFBYUUN3ME2xOk42OzZ3IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
KGN	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4rnVGlEPTB;MU[uOVU5PiEQvF2=	NVy3dXYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
PANC-03-27	Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{LYfGlEPTB;MU[uO\|Y3OiEQvF2=	M3PkSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
RH-1	Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1fxVGlEPTB;MU[uPFI2KM7:TR?=	M3yxUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HT-1376	M4Hocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3LXd2lEPTB;MU[uPFQ1PiEQvF2=	NHnmR3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
ZR-75-30	Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mo[yTWM2OD1zNj65N\|YyKM7:TR?=	M3nhTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
TI-73	NVz3c3BuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGmzOIhKSzVyPUG2Mlk1ODhizszN	NUDtV3dIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
TK10	M2\5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGH3cHZKSzVyPUG3MlAxPzlizszN	MkfWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SW684	MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmHqTWM2OD1zNz6wNVU1KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
RPMI-8866	MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYi5NXZGUUN3ME2xO{4xPjl7IN88US=>	Moj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
LNCaP-Clone-FGC	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M336VWlEPTB;MUeuOVIxOSEQvF2=	MnnTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H2291	NH3t[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmnxTWM2OD1zOD60N\|Q2KM7:TR?=	M1HzW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
T47D	M3PRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEHJZY5KSzVyPUG4MlQ5QCEQvF2=	NWW5TpBJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
A204	Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4C5OWlEPTB;MUiuOVQ2OiEQvF2=	Mke4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HT-144	NFfjb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M{PH[WlEPTB;MUiuO\|QzPyEQvF2=	MlXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
MDA-MB-361	NUnwRW5tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUD4RmNVUUN3ME2xPU4xPzF2IN88US=>	M4Ky[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HCC1806	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXHJR\|UxRTF7LkG1PVEh\|ryP	NEXXfVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H596	NVOxfYtUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2HQNmlEPTB;MUmuOlM6OSEQvF2=	Ml3YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
K-562	MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnvCTWM2OD1zOT64PVI3KM7:TR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
D-336MG	NHfu[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVLJR\|UxRTF7LkmzNlIh\|ryP	NHHYNo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-MEL-2	NITXbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmrHTWM2OD1{MD6xOVU6KM7:TR?=	NVTveGN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HEC-1	MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVHNc2xxUUN3ME2yNE41QTd6IN88US=>	M1HQbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
EW-13	M2nsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHzVV2VKSzVyPUKwMlU1PDNizszN	NHf4[4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
Hs-578-T	M1zpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWf0Z3BvUUN3ME2yNE42PTh\|IN88US=>	M17zd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SJSA-1	M4rTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4nESGlEPTB;MkCuOVY5QCEQvF2=	NGO2TY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
RCC10RGB	M3vLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NITCfXRKSzVyPUKwMlY4OTlizszN	M{nadlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
LAN-6	NFzHTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEnRXFNKSzVyPUKxMlA{QTZizszN	MnTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H1048	M3i5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGLNNYNKSzVyPUKxMlIzPThizszN	M4HmWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
CW-2	MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoG0TWM2OD1{MT6yO\|A2KM7:TR?=	MnTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HCC2157	M{n2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NH7sRlNKSzVyPUKxMlM3KM7:TR?=	M13CXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
EW-22	MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1LKcWlEPTB;MkGuN\|c3KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
A253	M{L2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHjkU45KSzVyPUKxMlQ1QDFizszN	NYTsc\|hyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
BE-13	Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoHpTWM2OD1{MT62NVE{KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
KINGS-1	NX\vfHpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mk[3TWM2OD1{MT62N\|E3KM7:TR?=	M2TMWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
ETK-1	Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2HBcGlEPTB;MkGuPFE2OiEQvF2=	MljvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H2452	MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MknTTWM2OD1{MT64OlQ4KM7:TR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
HPAF-II	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M37TRWlEPTB;MkGuPFkzOyEQvF2=	NWe5W2ljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
D-542MG	NFHkRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnTGTWM2OD1{MT65NFY6KM7:TR?=	MkDBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
NCI-H630	M3uydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVnJR\|UxRTJ{LkCyPVYh\|ryP	MlXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
TGBC11TKB	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWfYe3YzUUN3ME2yNk4xPDlizszN	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
BCPAP	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3vKRWlEPTB;MkKuOlEyKM7:TR?=	M4rCUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
HLE	Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NG[2d2dKSzVyPUKyMlY6PyEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H727	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2nlW2lEPTB;MkKuO\|M2KM7:TR?=	NUDMN4F{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
RD	MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmLITWM2OD1{Mj63OVE5KM7:TR?=	NHXNVFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H522	M3nmN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlniTWM2OD1{Mj64OFMyKM7:TR?=	MnLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CGTH-W-1	NUPpV2RPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWfScVhxUUN3ME2yN{4xPjRzIN88US=>	NHO4Omc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-LU-1	NVf2OI1TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUGzc\|czUUN3ME2yN{41Pjh\|IN88US=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
BB65-RCC	NFP6bVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFPBc5ZKSzVyPUKzMlc5PjNizszN	NFnSd2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HSC-3	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUDJR\|UxRTJ\|Lki1Nlch\|ryP	M{nXdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SK-MES-1	M4HKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV7JR\|UxRTJ2LkCxOlEh\|ryP	Ml62QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
DB	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2HTdmlEPTB;MkSuNVAzQCEQvF2=	NGWyfXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HO-1-N-1	M1nUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NILn[odKSzVyPUK0MlMxQTNizszN	NVjrR\|kyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MKN1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUmwfW1lUUN3ME2yOE43QCEQvF2=	NXnXcGlTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MN-60	NHvVNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mle0TWM2OD1{ND64OVE6KM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
8505C	NVvLVIdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVPhcWNIUUN3ME2yOU4yQDR3IN88US=>	NY\xR5FnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
COLO-320-HSR	M4Dzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUTJR\|UxRTJ3LkKyNFgh\|ryP	NFTKUWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
BB30-HNC	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUXJR\|UxRTJ3LkK0PFMh\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
KM12	NHjsO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVjJR\|UxRTJ3LkW4NFch\|ryP	NHrDdlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NB13	NYXsNpI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2L6S2lEPTB;MkWuOVg6QCEQvF2=	MoT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HCC2998	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoTyTWM2OD1{Nj6wNlg{KM7:TR?=	NGTuTZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
U-118-MG	NVr4OWRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4Tyd2lEPTB;Mk[uNFgxQCEQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NB10	M3zw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2HVWmlEPTB;Mk[uNlM1KM7:TR?=	NITmfWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SK-LMS-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3WxWWlEPTB;MkeuNFcxPCEQvF2=	Mkj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
SW1573	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWfhTHA2UUN3ME2yO{4yOSEQvF2=	MnrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
LB373-MEL-D	MoW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXzmRYtYUUN3ME2yO{4yOjl2IN88US=>	MkPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
DK-MG	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUnXRllsUUN3ME2yO{4yQDF5IN88US=>	NXnLPJQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
RMG-I	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2fESmlEPTB;MkeuNlAzQSEQvF2=	M{W0RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SW1088	NWfQS3FkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEfke4JKSzVyPUK3MlUxPDJizszN	NWTYSIlvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SK-OV-3	M2OyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2LIfGlEPTB;MkeuO\|U6OyEQvF2=	Ml;oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
KP-N-YN	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1n1SGlEPTB;MkeuPFA1OyEQvF2=	NEHIepY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
RPMI-7951	NYT3cGpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{PO[mlEPTB;MkiuNlQ2PiEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
CaR-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoHkTWM2OD1{OD61OVgzKM7:TR?=	NXL1cmQ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
MKN7	MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYK1WmN6UUN3ME2yPE42QTZ2IN88US=>	NFLqVFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
CHP-212	NVzJc49ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFPncG5KSzVyPUK4Mlc1ODFizszN	MnXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
KYSE-450	M{XuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoHHTWM2OD1{OD64NFkyKM7:TR?=	NGr4VZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
RXF393	NW\jemdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1n3T2lEPTB;MkmuNlkxPiEQvF2=	NXHDUHdWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
P30-OHK	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4r2fGlEPTB;MkmuN\|A1QCEQvF2=	MnK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
Ca9-22	M{jnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFH4XodKSzVyPUK5MlQzQTlizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
RT-112	NU\qRmUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4XvUGlEPTB;MkmuOFYyOSEQvF2=	NVz0RohIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
ES1	NEfhXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmOzTWM2OD1{OT64OVQ1KM7:TR?=	NXXnc29FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HCE-4	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1vFe2lEPTB;MkmuPFc5PiEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
AM-38	NYrpdG8{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1XIc2lEPTB;M{CuNFYxPiEQvF2=	M2XTTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
AsPC-1	Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGTuU41KSzVyPUOwMlgxPTNizszN	NV7oSo9tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
TE-9	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2DLcWlEPTB;M{CuPFc{PyEQvF2=	NYTNcGQ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
HuP-T4	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MY\JR\|UxRTNyLkm2N\|gh\|ryP	NUj6b\|drRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
LB2518-MEL	NYrBcHVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmDnTWM2OD1\|MT6wO\|Q1KM7:TR?=	M2niVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H1703	MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2nEN2lEPTB;M{GuNFkxPSEQvF2=	M1\tWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
NCI-H2228	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4PndWlEPTB;M{GuOFY2OSEQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SCC-4	NUfWdW9DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2rzeGlEPTB;M{GuPVE5OSEQvF2=	M2TtN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
KNS-81-FD	MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWHJR\|UxRTN{LkCxNlgh\|ryP	NIC1PYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NTERA-S-cl-D1	M{TjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUfJR\|UxRTN{LkC3N\|kh\|ryP	NIPGUGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
Daoy	NXO3SFJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIPndZdKSzVyPUOyMlA5OzhizszN	NHvjd3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
ES4	NHvwXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFTQemVKSzVyPUOyMlM6OjJizszN	NH\5e4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
MHH-ES-1	MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkLzTWM2OD1\|Mj60PFczKM7:TR?=	NGjMXHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
C-33-A	NY\MVFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NInQO\|dKSzVyPUOyMlc4OjhizszN	NHX4T2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
BHY	NYL4So5RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MluxTWM2OD1\|Mj65OFk2KM7:TR?=	M3XqTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
Detroit562	M4exWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWHY[oNqUUN3ME2zN{43PjV5IN88US=>	MljMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
EW-1	Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWjoT4VRUUN3ME2zN{46OzJ{IN88US=>	NIHaN3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
NCI-H1395	NYfqPHlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHSyUmdKSzVyPUO0MlA4QTlizszN	NV;P[2ptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KM-H2	MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEjURpNKSzVyPUO2MlQ4PDNizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H520	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEnGXlhKSzVyPUO2Mlc2PDFizszN	M3\3T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
D-392MG	Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{T1W2lEPTB;M{euN\|M1PCEQvF2=	NXjJNG1yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NOMO-1	MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{jqeWlEPTB;M{euPFA5QSEQvF2=	NXnIOW97RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
TE-6	MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXHJR\|UxRTN6LkGyOEDPxE1?	NF;tNnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HT-3	MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVLw[llCUUN3ME2zPE41PDN4IN88US=>	M3q0dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
RPMI-8226	NGDhe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3m2e2lEPTB;M{iuPVUyQSEQvF2=	M1HW[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
U251	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFyzfmJKSzVyPUO5MlAyOjRizszN	M1PCZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
GCT	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{TnT2lEPTB;M{muNVg2OiEQvF2=	NFL3U4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
A431	Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYnXNXlDUUN3ME2zPU4yQDl2IN88US=>	Ml73QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
TE-12	Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NX75NlRCUUN3ME2zPU4zPDR6IN88US=>	MnjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HMV-II	NIS5[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2jGR2lEPTB;M{muOVA1PyEQvF2=	NXiye5pzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
IST-MES1	NU\5VI5{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHX2XnFKSzVyPUSwMlE2ODJizszN	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SW13	MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmTLTWM2OD12MD61NVkh\|ryP	M4\wSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
SF295	M33INmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFznWWhKSzVyPUSwMlgxPjZizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
MDA-MB-157	M{njW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NGjDdlRKSzVyPUSwMlk1PjJizszN	NVOwcmd3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
TE-1	M4fBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXHMfZBvUUN3ME20NU45PzF2IN88US=>	NHrpOZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
HuCCT1	M{Sy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mnr2TWM2OD12Mj61Nlg6KM7:TR?=	NYXOVYJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
KYSE-510	NFq0WWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGTBbGJKSzVyPUSzMlE4PTRizszN	NXr4TmtkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
NCI-H358	MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4WzZmlEPTB;NESuNFMxPCEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
SW900	M{\QZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVnJR\|UxRTR2LkC3OVgh\|ryP	NWi4PVg2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CAS-1	NUPJfmoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkXPTWM2OD12ND6wPVkyKM7:TR?=	M3zBfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
TE-8	Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXrJR\|UxRTR2LkW2OVgh\|ryP	NGjNeVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
P12-ICHIKAWA	NFvXc\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWDJR\|UxRTR2Lk[xNVIh\|ryP	M{G4T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
YKG-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUPJR\|UxRTR2Lke4NUDPxE1?	NXfjdXFWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
SNU-C2B	M4LlRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NVT4TFFMUUN3ME20OE44QTB\|IN88US=>	MljDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
LCLC-103H	NFfDR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlvWTWM2OD12ND64O\|A{KM7:TR?=	NGLX[FM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
U-87-MG	Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3;JcGlEPTB;NEWuNVAzOiEQvF2=	MlX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
HAL-01	NGjUcW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHHweHVKSzVyPUS1MlE{PzlizszN	NIjseW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
OVCAR-8	NF73U2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGLxeIxKSzVyPUS1MlM2PjRizszN	Mmf2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
KYSE-150	NIjEdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXr5dWlSUUN3ME20O{4yODV{IN88US=>	NXf0NVZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
OE33	NHqzZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWjhdIVMUUN3ME20O{4yPDJ7IN88US=>	NF7Kb4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
CAL-62	NXfQT\|JFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEPyd2pKSzVyPUS3MlQxPjhizszN	NIDDbIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
TCCSUP	M2H4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NV21c\|AzUUN3ME20O{43OjZ2IN88US=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
H4	NGjWWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIH3dW9KSzVyPUS3MlY3OjFizszN	NV;zZlduRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh6Nke4M{c,W0GQR1XSQE9iRg>?
CP66-MEL	NHXLcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NI\tfIFKSzVyPUS4MlA4ODRizszN	NHj6bFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
SNB75	MnLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnrtTWM2OD12OD6xPFc1KM7:TR?=	M33NOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QDZ5OD:nQnNCVkeHUkyvZV4>
Mo-T	M4rPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHHtS4FKSzVyPUS4MlI4QSEQvF2=	MlexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
BT-549	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NX74W4xTUUN3ME20PE4{PzJ7IN88US=>	Mk\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
IGR-1	NWjadXBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2TiRWlEPTB;NEiuOlY1PSEQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFg3PzhxJ{7TRW5ITVJ:L3G+
NCI-H1299	NYWyN49iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmXTTWM2OD12OD63NlQ5KM7:TR?=	NHiwc4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDh4N{ivK\|5USU6JRWK8M4E,
ALL-PO	MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2rjNWlEPTB;NEmuPVI3QCEQvF2=	MkmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg5Pjd6Lze+V2FPT0WUPD;hQi=>
CLL	MXjGeY5kfGmxbjDhd5NigQ>?			M4jnS2lvcGmkaYTpc44hd2ZiRF7BMXBMKGG3dH;wbI9{eGixconsZZRqd25iYYSgV4VzOjB3NjDy[ZNq\HWnIHnuJIh2dWGwIFPMUEBk\WyuczDifUBY\XO2ZYLuJIJtd3RibXX0bI9lNCCLQ{WwJF0hOC5yMzFOwG0v	M3TpWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEO1PFcxLz5{MkizOVg4ODxxYU6=
HeLa	M4rsZ2Z2dmO2aX;uJIF{e2G7			NXvNfG56UW6qaXLpeIlwdiCxZjDEUmEuWEtiYYX0c5Bpd3OyaH;yfYxifGmxbjDheEBUOjB3NjDpckBpfW2jbjDI[WxiKGOnbHzzMEBGSzVyIE2gNE4zOTJizszNMi=>	MnnPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NUW4N\|YoRjJ\|OEW1PFM3RC:jPh?=
CHO	NHrTSVhHfW6ldHnvckBie3OjeR?=			NWT4[4V6UW6qaXLpeIlwdiCxZjDoeY1idiCHUleg[ZhxemW\|c3XkJIlvKGOrc3Hwdoll\SC2cnXheIVlKEOKTzDj[YxteyCkeTDJc44hX2:{a4OgZZN{[XluIFnDOVAhRSBzNDFOwG0v	NIDuRlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i1OVg{Pid-MkO4OVU5OzZ:L3G+
A673	NHjIbHVyUFSVIHHzd4F6			M{LrXJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	MoftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	NIrMS3JyUFSVIHHzd4F6			MlHMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	MnjuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	M{PKWJFJXFNiYYPzZZk>			NHe1SnJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	M3vrcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	M3jWRpFJXFNiYYPzZZk>			NHntSVhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN\|ch[2WubIO=	M3vHUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MWHxTHRUKGG\|c3H5			M1;mZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	MofhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	MY\xTHRUKGG\|c3H5			M1i2bJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?=	M1LESVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	MmPLdWhVWyCjc4PhfS=>			NVnMUW5keUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	MofSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	MnradWhVWyCjc4PhfS=>			MlvwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	NHHlTYdyUFSVIHHzd4F6			M{\RcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	M1jVelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NV7aRWZueUiWUzDhd5NigQ>?			M1vDb5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	MU\xTHRUKGG\|c3H5			MmPVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	M2KzSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	NWn6TVJOeUiWUzDhd5NigQ>?			MVXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	NH7YUGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	Mo\GdWhVWyCjc4PhfS=>			NUH6PWNZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	M3K0[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	MYfxTHRUKGG\|c3H5			MVnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
INA-6	NVPo[lk2TnWwY4Tpc44h[XO\|YYm=	MlPGNVAhfU1?	NXW4XlBoPCCqcoO=	M4nJXWlvcGmkaYTpc44hd2ZiaHXheEB{cG:lazDy[ZNxd26\|ZTDpckBpfW2jbjDJUmEuPiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gTHNHNTFibXXkbYF1\WRidYDy[Yd2dGG2aX;uJI9nKHSqZTDIV3A4OiCycn;0[YlvKGW6cILld5Nqd25iYYSgNVAhfU1icILlbY5kfWKjdHXkJIZweiB2IHjyd{Bnd2yub4fl[EBjgSCKU2C5NEBqdmirYnn0c5Ih[W6mIFjTVkBqdmS3Y3XyJG5XWC2DVWm5NlIh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgOEBpeg>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR3M{mzNUc,Ojh2NUO5N\|E9N2F-
INA-6	M{\5[2Z2dmO2aX;uJIF{e2G7	NVTDe2FLOTBidV2=	NIqzTlY1KGi{cx?=	NGjBVY1KdmirYnn0bY9vKG:oIHjlZZQhe2ixY3ugdoV{eG:wc3WgbY4hcHWvYX6gTW5CNTZiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGhUTi1zIH3l[IlifGWmIIXwdoVofWyjdHnvckBw\iC2aHWgTHNRPzJibWLORUBmgHC{ZYPzbY9vKGG2IEGwJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhPCCqcoOg[o9tdG:5ZXSgZpkhUFOSOUCgbY5pcWKrdH;yJIFv\CCKU2KgbY5lfWOncjDOWnAuSVW\OUKyJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IESgbJJ{KGJ?	M4mydlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEWzPVMyLz5{OES1N\|k{OTxxYU6=
INA-6	NHziVZhHfW6ldHnvckBie3OjeR?=	MWmxNEB2VQ>?	NU\GUW5{PCCqcoO=	M4j6fmRwf26{ZXf1cIF1cW:wIH;mJG5XWC2DVWm5NlIucW6mdXPl[EBJW0ZvMTDwdo91\WmwIHX4dJJme3Orb36gbY4hcHWvYX6gTW5CNTZiY3XscJMh[XRiMUCgeW0heHKnaX7jeYJifGWmIH\vdkA1KGi{czDmc4xtd3enZDDifUBPXlBvQWXZPVIzKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFQhcHK\|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q>	NFX6OIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES1N\|k{OSd-Mki0OVM6OzF:L3G+
INA-6	NYLpZXB4TnWwY4Tpc44h[XO\|YYm=	NGO4eW0yOCC3TR?=	MX20JIhzew>?	NIntVoJKdmirYnn0bY9vKG:oIF7WVE1CXVl7MkKtbY5lfWOnZDDIV2YuOSCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUU6DLU[gZ4VtdHNiYYSgNVAhfU1icILlbY5kfWKjdHXkJIZweiB2IHjyd{Bnd2yub4fl[EBjgSCQVmCtRXV[QTJ{IHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDt[ZRpd2R?	M17ZcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEWzPVMyLz5{OES1N\|k{OTxxYU6=
INA-6	MkHUSpVv[3Srb36gZZN{[Xl?	M3P1R\|ExKHWP	MnPjOEBpenN?	NYjRfG1NTG:5boLl[5Vt[XSrb36gc4YhVl[SLVHVXVkzOi2rbnT1Z4VlKEiVRj2xJI1TVkFiZYjwdoV{e2mxbjDpckBpfW2jbjDJUmEuPiClZXzsd{BifCBzMDD1UUBxemWrbnP1ZoF1\WRiZn;yJFQhcHK\|IH\vcIxwf2WmIHL5JG5XWC2DVWm5NlIh[WSmaYTpc44hdWWjc4Xy[YQh[W[2ZYKgOEBpenNiYomgVnQuWEOUIH3leIhw\A>?	NEX2cms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES1N\|k{OSd-Mki0OVM6OzF:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-DNA-PKcs / DNA-PKcs / p-ATM / ATM / p-ATR / ATR / Ku70 / p-CHK1 / p-CHK2/ p-AKT / RAD51; PubMed: 29344644 Oncol Rep SUNE1 cells were irradiated with 5 Gy in the presence or absence of NU7441 (2 µM). The expression of cell cycle checkpoint proteins and double strand break repair proteins was assayed by western blot analysis at 6 or 12 h post-IR. p-mTOR(Ser2448) / mTOR / p-S6K(Thr389); PubMed: 25714019 Oncotarget Phosphorylation of mTOR and p70S6K were detected by Western blot analysis 24 hours after treatment.	29344644 25714019

In vivo

NU7441 intraperitoneally administrated at dose of 10 mg/kg maintains for at least 4 hours shows nontoxic and increases etoposide-induced tumor growth delay 2-fold in mice bearing SW620 xenografts. ^[2]

Protocol

Cell Research:

^[2]

- Collapse

Cell lines: SW620, LoVo, V3-YAC and V3 cells
Concentrations: 0.5 μM or 1 μM
Incubation Time: 17 hours
Method:
The effect of NU7441 on cellular survival following exposure to etoposide, doxorubicin, and ionizing radiation is measured in SW620, LoVo, V3, and V3-YAC cells by clonogenic assays. Briefly, growing cells in six-well plates or 6-cm dishes are exposed to etoposide or doxorubicin with or without NU7441 (0.5 or 1.0 μM) for 16 hours. For radiosensitization studies, NU7441 is added to the cells 1 hour before irradiation. V3 and V3-YAC cells are exposed to γ-irradiation (3.1 Gy/min ¹³⁷Cesium). SW620 and LoVo are exposed to X-irradiation (2.9 Gy/min at 230 kV, 10 mA) due to the equipment available. After irradiation, the cells are incubated with or without NU7441 for a further 16 hours. Cells are then harvested by trypsinization, counted, and seeded into 10-cm diameter Petri dishes at densities varying from 100 to 10⁵ per dish in drug-free medium for colony formation. Colonies are stained with crystal violet after 10 to 14 days and counted with an automated colony counter. The survival reduction factor (SRF) is calculated as the surviving fraction of cells in the absence of NU7441 divided by the surviving fraction of cells in the presence of NU7441 for any given dose or concentration of cytotoxic agent. The dose modification ratio (DMR90) is calculated as the concentration/dose of cytotoxic agent required to kill 90% of the cells in the absence of NU7441 divided by the concentration/dose of cytotoxic agent required to kill 90% of the cells in the presence of NU7441.

(Only for Reference)

Animal Research:

^[2]

- Collapse

Animal Models: Female rude mice bearing SW620 xenografts
Dosages: 10 mg/kg
Administration: Intraperitoneally administrated
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	4 mg/mL warmed (9.67 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O For best results, use promptly after mixing.	0.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download NU7441 (KU-57788) SDF

Molecular Weight	413.49
Formula	C₂₅H₁₉NO₃S
CAS No.	503468-95-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC5=C4SC6=CC=CC=C56

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Could you please suggest formulations of the drug for in vivo injection?
Answer:
We tested the following formulation for in vivo use, 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 1mg/mL. It is a clear solution.
Question 2:
Previous aliquots were clear and colorless while this time, it becomes yellow when the powder was dissolved in DMSO? Could you advice on this?
Answer:
Slight color variation due to different processing is normal and usually doesn't interfere with the function.

DNA-PK Signaling Pathway Map

DNA-PK Inhibitors with Unique Features

Non-specific DNA-PK Inhibitor

PI-103 : DNA-PK, IC50=23 nM; p110α/β/δ/γ, IC50=2 nM/3 nM/3 nM/15 nM; mTOR, IC50=30 nM.
Most Potent DNA-PK Inhibitor

PIK-75 : DNA-PK, IC50=2 nM.
Newest DNA-PK Inhibitor

KU-0060648 : Dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Classic DNA-PK Inhibitor

NU7026 : Potent DNA-PK inhibitor with IC50 of 0.23 μM, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR.

Related DNA-PK Products

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin (Compound C, BML-275) is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy. For animal testing, the water-soluble S7306 Dorsomorphin (Compound C) 2HCl is recommended.
MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
NU7026

NU7026 (LY293646) is a potent DNA-PK inhibitor with IC50 of 0.23 μM in cell-free assays, 60-fold selective for DNA-PK than PI3K and inactive against both ATM and ATR. NU7026 enhances G2/M cell arrest and apoptosis.
KU-0060648

KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
Rapamycin (AY-22989)

Rapamycin (AY-22989, Rapamune, Sirolimus, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.

Choose Your Country or Region

By Signaling Pathways

By product type

NU7441 (KU-57788)